The downward adjustment for an ER+ HER2+ breast cancer is only from 6.5 to 4.7% whereas the current report only identified mutations in 4.5% of ER+ HER2+ breast cancers when the average detection rate in ER+ HER2− breast cancer was 14.8% (Table 1). The gene discussed is ESR1; the disease is breast carcinoma.